89 related articles for article (PubMed ID: 28982893)
1. The Significance of PET/CT in the Initial Staging of Hodgkin Lymphoma: Experience Outside Clinical Trials.
Angelopoulou MK; Mosa E; Pangalis GA; Rondogianni P; Chatziioannou S; Prassopoulos V; Moschogianni M; Tsirkinidis P; Asimakopoulos JV; Konstantinou I; Tsourouflis G; Sachanas S; Yiakoumis X; Boutsikas G; Arapaki M; Gainaru G; Kyrtsonis MC; Siakantaris MP; Datseris I; Panayiotidis P; Konstantopoulos K; Vassilakopoulos TP
Anticancer Res; 2017 Oct; 37(10):5727-5736. PubMed ID: 28982893
[TBL] [Abstract][Full Text] [Related]
2. Can Positron Emission Tomography and Computed Tomography Be a Substitute for Bone Marrow Biopsy in Detection of Bone Marrow Involvement in Patients with Hodgkin's or Non-Hodgkin's Lymphoma?
Çetin G; Çıkrıkçıoğlu MA; Özkan T; Karatoprak C; Ar MC; Eşkazan AE; Ayer M; Cerit A; Gözübenli K; Uysal BB; Erdem S; Ergül N; Tatar G; Çermik TF
Turk J Haematol; 2015 Sep; 32(3):213-9. PubMed ID: 25912844
[TBL] [Abstract][Full Text] [Related]
3. Role of bone marrow biopsy in staging of patients with classical Hodgkin's lymphoma undergoing positron emission tomography/computed tomography.
Puccini B; Nassi L; Minoia C; Volpetti S; Ciancia R; Riccomagno PC; Di Rocco A; Mulè A; Toldo C; Sassone MC; Guariglia R; Filì C; Finolezzi E; Falorio S; Zanon S; Furlan A; Doa G; Zaja F;
Ann Hematol; 2017 Jul; 96(7):1147-1153. PubMed ID: 28451805
[TBL] [Abstract][Full Text] [Related]
4. Interim 18F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients.
Rossi C; Kanoun S; Berriolo-Riedinger A; Dygai-Cochet I; Humbert O; Legouge C; Chrétien ML; Bastie JN; Brunotte F; Casasnovas RO
J Nucl Med; 2014 Apr; 55(4):569-73. PubMed ID: 24566003
[TBL] [Abstract][Full Text] [Related]
5. Predictive value of (18)F-FDG PET/CT in restaging patients affected by ovarian carcinoma: a multicentre study.
Caobelli F; Alongi P; Evangelista L; Picchio M; Saladini G; Rensi M; Geatti O; Castello A; Laghai I; Popescu CE; Dolci C; Crivellaro C; Seghezzi S; Kirienko M; De Biasi V; Cocciolillo F; Quartuccio N;
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):404-13. PubMed ID: 26381775
[TBL] [Abstract][Full Text] [Related]
6. The value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for staging of primary extranodal head and neck lymphomas.
Schrepfer T; Haerle SK; Strobel K; Schaefer N; Hälg RA; Huber GF
Laryngoscope; 2010 May; 120(5):937-44. PubMed ID: 20422687
[TBL] [Abstract][Full Text] [Related]
7. Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma.
El-Galaly TC; d'Amore F; Mylam KJ; de Nully Brown P; Bøgsted M; Bukh A; Specht L; Loft A; Iyer V; Hjorthaug K; Nielsen AL; Christiansen I; Madsen C; Johnsen HE; Hutchings M
J Clin Oncol; 2012 Dec; 30(36):4508-14. PubMed ID: 23150698
[TBL] [Abstract][Full Text] [Related]
8. Interim FDG-PET/CT in Hodgkin lymphoma: the prognostic role of the ratio between target lesion and liver SUVmax (rPET).
Annunziata S; Cuccaro A; Calcagni ML; Hohaus S; Giordano A; Rufini V
Ann Nucl Med; 2016 Oct; 30(8):588-92. PubMed ID: 27246952
[TBL] [Abstract][Full Text] [Related]
9. The prognostic value of positron emission tomography performed after two courses (INTERIM-PET) of standard therapy on treatment outcome in early stage Hodgkin lymphoma: A multicentric study by the fondazione italiana linfomi (FIL).
Rigacci L; Puccini B; Zinzani PL; Biggi A; Castagnoli A; Merli F; Balzarotti M; Stelitano C; Spina M; Vitolo U; Stefoni V; Levis A; Gotti M; Rosaria S; Maria SP; Bosi A; Gallamini A
Am J Hematol; 2015 Jun; 90(6):499-503. PubMed ID: 25720750
[TBL] [Abstract][Full Text] [Related]
10. Real-life Experience for Integration of PET-CT in the Treatment of Hodgkin Lymphoma in Lebanon.
Sakr R; Massoud M; Kerbage F; Rached L; Zeghondy J; Akoury E; Nasr F; Chahine G
Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S92-S95. PubMed ID: 28760308
[TBL] [Abstract][Full Text] [Related]
11. Interim Positron Emission Tomography Response-Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study.
Zinzani PL; Broccoli A; Gioia DM; Castagnoli A; Ciccone G; Evangelista A; Santoro A; Ricardi U; Bonfichi M; Brusamolino E; Rossi G; Anastasia A; Zaja F; Vitolo U; Pavone V; Pulsoni A; Rigacci L; Gaidano G; Stelitano C; Salvi F; Rusconi C; Tani M; Freilone R; Pregno P; Borsatti E; Sacchetti GM; Argnani L; Levis A
J Clin Oncol; 2016 Apr; 34(12):1376-85. PubMed ID: 26884559
[TBL] [Abstract][Full Text] [Related]
12. Positron Emission Tomography Scanning in the Management of Hodgkin Lymphoma Patients: A Single-Institution Experience.
Zabrocka E; Sierko E; Wojtukiewicz MZ
Adv Clin Exp Med; 2016; 25(6):1185-1192. PubMed ID: 28028972
[TBL] [Abstract][Full Text] [Related]
13. Effect of PET/CT on the Management and Outcomes of Participants with Hodgkin and Aggressive Non-Hodgkin Lymphoma: A Multicenter Registry.
Metser U; Prica A; Hodgson DC; Mozuraitis M; Eberg M; Mak V; Green B; Singnurkar A; Dudebout J; MacCrostie P; Tau N; Mittmann N; Langer DL
Radiology; 2019 Feb; 290(2):488-495. PubMed ID: 30511907
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic and prognostic role of PET/CT in patients with chronic lymphocytic leukemia and progressive disease.
Mauro FR; Chauvie S; Paoloni F; Biggi A; Cimino G; Rago A; Gentile M; Morabito F; Coscia M; Bellò M; Sacchetti GM; Rossi D; Laurenti L; Autore F; Campanelli M; Trastulli F; Nicolai E; Riminucci M; Gaidano G; Guarini A; Gallamini A; Foà R
Leukemia; 2015 Jun; 29(6):1360-5. PubMed ID: 25650091
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic accuracy of FDG PET/CT for clinical evaluation at the end of treatment of HL and NHL: a comparison of the Deauville Criteria (DC) and the International Harmonization Project Criteria (IHPC).
Fallanca F; Alongi P; Incerti E; Gianolli L; Picchio M; Kayani I; Bomanji J
Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1837-48. PubMed ID: 27154522
[TBL] [Abstract][Full Text] [Related]
16. Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging--do we need contrast-enhanced CT?
Schaefer NG; Hany TF; Taverna C; Seifert B; Stumpe KD; von Schulthess GK; Goerres GW
Radiology; 2004 Sep; 232(3):823-9. PubMed ID: 15273335
[TBL] [Abstract][Full Text] [Related]
17. Impact of PET-CT on involved field radiotherapy design for pediatric Hodgkin lymphoma.
Paulino AC; Margolin J; Dreyer Z; Teh BS; Chiang S
Pediatr Blood Cancer; 2012 Jun; 58(6):860-4. PubMed ID: 21826784
[TBL] [Abstract][Full Text] [Related]
18. Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy--is biopsy of FDG-avid lesions still needed?
Schaefer NG; Taverna C; Strobel K; Wastl C; Kurrer M; Hany TF
Radiology; 2007 Jul; 244(1):257-62. PubMed ID: 17581905
[TBL] [Abstract][Full Text] [Related]
19. Prognostic values of interim and post-therapy 18F-FDG PET/CT scanning in adult patients with Burkitt's lymphoma.
Wei WX; Huang JJ; Li WY; Zhang X; Xia Y; Jiang WQ; Fan W; Li ZM
Chin J Cancer; 2015 Dec; 34(12):608-13. PubMed ID: 26630874
[TBL] [Abstract][Full Text] [Related]
20. Positron emission tomography in the staging of patients with Hodgkin's lymphoma. A prospective multicentric study by the Intergruppo Italiano Linfomi.
Rigacci L; Vitolo U; Nassi L; Merli F; Gallamini A; Pregno P; Alvarez I; Salvi F; Sancetta R; Castagnoli A; Versari A; Biggi A; Gregianin M; Pelosi E; Chisesi T; Bosi A; Levis A;
Ann Hematol; 2007 Dec; 86(12):897-903. PubMed ID: 17701410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
